Voronoi, Inc.
Financials
Valuation Metrics
Voronoi, Inc.'s Market Cap is ₩2.5T. At end of 2025 it was ₩4.0T. Ranked #165 of 2,436 in KR market (top 7%), #28 of 1,649 on KOSDAQ (top 2%), #18 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 8%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.54T KRW | KR#165/2,436 Sec#18/234 |
| Revenue | 7.51B KRW | KR#2,314/2,436 Sec#185/234 |
| Net Income | -50.60B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 158.75B KRW | KR#1,435/2,436 Sec#113/234 |
| Net Assets | 91.85B KRW | KR#1,457/2,436 Sec#119/234 |
| Employees | 147 | KR#1,336/2,436 Sec#108/234 |
| Value | ||
| P/B | 27.61x | KR#2,395/2,436 Sec#224/234 |
| P/S | 337.57x | KR#2,405/2,436 Sec#221/234 |
| FCF Yield | -2.91% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -55.09% | KR#2,281/2,436 Sec#202/234 |
| ROA | -31.87% | KR#2,313/2,436 Sec#205/234 |
| Op. Margin | -824.00% | KR#2,386/2,436 Sec#215/234 |
| Financial Health | ||
| Debt Ratio | 172.84% | KR#1,468/2,436 Sec#167/234 |
| Total Debt | 32.70B KRW | KR#1,155/2,436 Sec#88/234 |
| FCF | -73.74B KRW | KR#2,119/2,436 Sec#210/234 |
| Cash | 13.53B KRW | KR#1,492/2,436 Sec#110/234 |
| Current Ratio | 11.19x | KR#84/2,436 Sec#22/234 |
| Performance | ||
| 1Y Return | 21.15% | KR#419/2,436 Sec#35/234 |
| 1M Return | -23.14% | KR#2,272/2,436 Sec#225/234 |
| From 52W High | -63.38% | KR#1,876/2,436 Sec#159/234 |
| 1Y MDD | -72.27% | KR#2,044/2,436 Sec#181/234 |
| Trading | ||
| Volume | 170,004 shares | KR#654/2,436 Sec#64/234 |
| Foreign Own. | 8.23% | KR#546/2,436 Sec#49/234 |
| Per Share | ||
| EPS | -2,751 KRW | KR—/2,436 Sec—/234 |
| BPS | 5,010 KRW | KR#1,437/2,436 Sec#107/234 |
Company Info
Established in 2015 in Songdo, Incheon, VORONOI is a new drug development venture company with its own medicinal chemistry research institute. It specializes in developing targeted anticancer drugs for conditions like lung and breast cancer, with VRN11 currently undergoing global clinical phase 1 trials after approvals in Korea, Taiwan, and Hong Kong. The company utilizes its Voronomix platform to accelerate drug development from target selection to candidate substance in 1-1.5 years, demonstrating competitiveness through five technology transfer achievements since 2020. VORONOI is headquartered in Yeonsu-gu, Incheon Metropolitan City.